Mirion Raises 2026 Revenue Outlook as Q3 Orders Surge

TradingKey10-29

Mirion said stronger backlog conversion and surging nuclear-power demand supported a 24.5% increase in third-quarter revenue, prompting the company to raise its full-year 2026 revenue guidance. Orders climbed 62% excluding acquisitions, while the company expects organic revenue growth to reach the mid-to-high teens in the fourth quarter.

Revenue for the quarter ended September 30 rose to $277.8 million from $223.1 million a year earlier. Organic revenue increased 6.5%, acquisitions contributed 18.6 percentage points of growth, and foreign exchange reduced growth by 0.6 percentage point.

Adjusted EBITDA advanced 23.7% to $64.8 million, although the adjusted EBITDA margin edged down to 23.3% from 23.5%. Adjusted diluted earnings were unchanged at $0.12 per share. Mirion noted that its calculation began including stock-based compensation in the first quarter of 2026; excluding stock-based compensation, the comparable third-quarter 2025 figure was $0.11 per share.

Orders and backlog strengthen revenue visibility

Third-quarter orders reached $386 million, up 85% on a reported basis and 62% excluding M&A. Nuclear Power end-market orders more than doubled excluding acquisitions, supported by new-build and installed-base activity. Medical orders also grew across all three end markets, led by radiation therapy quality assurance, or RTQA.

Mirion received $140 million of large-opportunity awards during the quarter, or $122 million after a China de-booking. The company said it had lost none of the large opportunities awarded year to date and identified about $125 million of additional opportunities targeted for the fourth quarter. These projects span small modular reactors, radioactive waste, nuclear new builds, operating-fleet reactors, radiation cameras, RTQA and U.S. Department of Energy-related work.

Backlog totaled $1.25 billion at quarter-end, up 53% year over year, including acquisitions. Excluding M&A, backlog increased 33%. Nuclear Power accounted for 63% of the total, while installed-base backlog excluding acquisitions rose 55% to $326 million.

About 59% of the third-quarter backlog is expected to be recognized in the fourth quarter of 2026 and during 2027. Mirion had generated $802 million of revenue through September and expects $292 million of backlog conversion in the fourth quarter, providing 95% coverage of full-year revenue at the midpoint of guidance. The remaining requirement largely reflects the Medical segment’s book-and-bill business, along with Paragon revenue that is not included in backlog.

Nuclear & Safety leads reported growth

Nuclear & Safety revenue rose 34.2% to $194.0 million, including 6.3% organic growth and a 28.7-percentage-point contribution from acquisitions. Nuclear Power organic revenue increased 14%, driven by installed-base and small modular reactor activity. SMR-related orders reached $16 million in the quarter and $54 million year to date, with the nine-month total up 106%.

The segment’s adjusted EBITDA increased 22.7% to $49.8 million, but its margin declined to 25.7% from 28.1%. Mirion attributed the contraction to dilution from the Paragon acquisition, business mix and lower incentive compensation in the prior-year period. Paragon revenue grew 12% from the third quarter of 2025 and 22% on a year-to-date basis.

Medical revenue increased 6.7% organically and on a reported basis to $83.8 million. All three Medical end markets contributed to growth, with RTQA providing the largest increase on continued performance from original-equipment-manufacturer customers. Adjusted EBITDA rose 12.4% to $31.7 million, lifting the segment margin to 37.8% from 35.9%.

Cash generation improves as Mirion updates guidance

Mirion generated $47 million of adjusted free cash flow in the quarter. Year-to-date adjusted free cash flow more than doubled to $107.5 million from $53.1 million, and conversion improved to 58% of adjusted EBITDA from 35%. Management expects net working capital to be a source of cash in the fourth quarter and approximately neutral for the full year.

The company now forecasts 2026 total revenue growth of about 24% to 25%, equivalent to approximately $1.147 billion to $1.157 billion. Organic revenue growth is expected to be about 7% to 8%. Mirion projects adjusted EBITDA of roughly $285 million to $292 million, representing a margin of about 24.7% to 25.2%, and adjusted earnings of $0.50 to $0.54 per share.

Adjusted free cash flow is expected to range from about $170 million to $185 million, with conversion of 60% to 63% of adjusted EBITDA. For the fourth quarter, management anticipates mid-single-digit-plus organic growth in Medical and high-teens-plus growth in Nuclear & Safety.

Net leverage stood at 3.1 times at the end of September, or 2.8 times excluding opportunistic share repurchases. Mirion expects the ratio to decline to about 2.6 times by year-end, assuming no additional fourth-quarter repurchases, acquisitions or capital raises.

Mirion repurchased approximately 3.6 million shares for $56 million during the quarter, completing its $100 million buyback program. It subsequently introduced a new $250 million program, with $235 million remaining at the time of the presentation.

The outlook remains subject to customer procurement and project timing, the conversion of backlog into revenue, government budgets, supply-chain conditions, inflation, foreign exchange movements and geopolitical or trade disruptions. Mirion’s guidance assumes a fourth-quarter euro-to-dollar exchange rate of 1.12; the company estimates that each $0.01 movement would affect annualized revenue by about $3.5 million and adjusted EBITDA by about $1 million.

Find out more

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment